Vaccination with a HER2/neu peptide induces intra- and inter-antigenic epitope spreading in patients with early stage breast cancer
- 1 March 2006
- journal article
- Published by Elsevier BV in Surgery
- Vol. 139 (3), 407-418
- https://doi.org/10.1016/j.surg.2005.06.059
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Clinical Trial Results of a HER2/neu (E75) Vaccine to Prevent Recurrence in High-Risk Breast Cancer PatientsJournal of Clinical Oncology, 2005
- Direct Measurement of Peptide-Specific CD8+ T Cells Using HLA-A2:Ig Dimer for Monitoring the In Vivo Immune Response to a HER2/neu Vaccine in Breast and Prostate Cancer PatientsJournal of Clinical Immunology, 2004
- Generation of T-Cell Immunity to the HER-2/neu Protein After Active Immunization With HER-2/neu Peptide–Based VaccinesJournal of Clinical Oncology, 2002
- Induction of determinant spreading and of Th1 responses by in vitro stimulation with HER-2 peptidesCancer Immunology, Immunotherapy, 2000
- Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cellsBlood, 2000
- Driver Clones and Determinant SpreadingJournal of Autoimmunity, 2000
- Epitope spreadingCurrent Opinion in Immunology, 1996
- Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide.Proceedings of the National Academy of Sciences, 1995
- Cellular Mucins: Targets for ImmunotherapyCritical Reviews in Immunology, 1994
- Spreading of T-cell autoimmunity to cryptic determinants of an autoantigenNature, 1992